(NASDAQ: FBRX) Forte Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.04%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.57%.
Forte Biosciences's earnings in 2026 is -$69,375,000.On average, 8 Wall Street analysts forecast FBRX's earnings for 2026 to be -$58,296,200, with the lowest FBRX earnings forecast at -$65,998,580, and the highest FBRX earnings forecast at -$39,657,468. On average, 7 Wall Street analysts forecast FBRX's earnings for 2027 to be -$61,496,846, with the lowest FBRX earnings forecast at -$80,150,853, and the highest FBRX earnings forecast at -$33,242,289.
In 2028, FBRX is forecast to generate -$66,426,259 in earnings, with the lowest earnings forecast at -$80,695,171 and the highest earnings forecast at -$30,034,700.